A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer

Completed

• Conditions: SMARCA4-Deficient Tumor; NSCLC (Advanced Non-small Cell Lung Cancer)

• Registration Number: NCT07121387
• Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Brief Summary

This is a single-center retrospective analysis to explore the clinical characteristics, therapeutic efficacy, and tumor immune microenvironment of SMARCA4-deficient advanced non-small-cell lung cancer (NSCLC).

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-01
• Primary Completion: 2024-12-17
• Study Completion: 2024-12-17
• Status Verified: 2025-08
• Study First Submitted: 2025-08-06
• Study First Submitted QC: 2025-08-06
• Last Update Submitted: 2025-08-06
• Study First Posted: 2025-08-13
• Last Update Posted: 2025-08-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 221

Inclusion Criteria

• Diagnosed with stage III-IV NSCLC according to the American Joint Committee on Cancer staging criteria (7th edition);
• Lesions are measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
• Receiving first-line immunotherapy or chemotherapy as anti-tumor treatment.

Exclusion Criteria

• SMARCA4 gene test was not performed;
• Not receive treatment;
• Lost to follow-up after one treatment cycle.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival (PFS)	5 years	Time from the beginning of first-line therapy to the first progression (PD) in patients with lung cancer

Secondary Outcome Measures

Name	Time	Method
Overall survival (OS)	5 years	Overall survival (OS) is defined as the duration from the beginning of first-line therapy until death due to any cause. Subjects who are still alive at the end of the study observation period will be censored at the time of last known vital status.
Objective Response Rate (ORR)	5 years	The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Disease control rate (DCR)	5 years	Disease control rate (DCR) was defined as the proportion of patients achieving complete response (CR), partial response (PR), or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Trial Locations

Locations (1)

Shanghai Pulmonary Hospital; 🇨🇳 Shanghai, China